Certificate of Analysis

Report GSA-COA-000078-RETA60-20261031-8
Issued 2026-11-04 · Page 1 of 2

Scan to verify

Retatrutide 60 mg

Order GSA-2026-000078 · 6A Labs · 3 vials of one product

Customer	6A Labs
Order	GSA-2026-000078
Label	Retatrutide 60 mg
Vials tested	3 (D3, E3, F3)
Prepared	29 Oct 2026
Tested	31 Oct 2026, 02 Nov 2026
Tests	Identity, Purity, Content, Impurities, Conformity

IDENTITY

Retatrutide


confirmed in all 3 vials

PURITY


99.8 %

mean of 3 vials (99.6-99.9 %)

HPLC chromatograms (UV, 214 nm), every vial



Mass spectrum of the main peak, vial D3 (8.84 min)



Results by vial

Vial	Identity	Purity (214 nm)
Vial D3	Confirmed	99.95 %
Vial E3	Confirmed	99.57 %
Vial F3	Confirmed	99.87 %
Average		**99.80 %**
Difference		**0.38 points**

Difference = largest minus smallest vial. Purity is a share of the UV peak area.

APPROVED FOR RELEASE

Ian Ebert, Laboratory Director

Signed electronically
5 Nov 2026, 04:46 UTC
Release record: last page

Results are not covered by ISO/IEC 17025 accreditation.
Results relate only to the sample as received and tested.

Results

Identity	**Identified as retatrutide in every vial.** Measured mass 4731.1, 4731.1, 4731.1 (average 4731.1; expected 4731.3); retention time matching the retatrutide reference standard (8.89 min). No semaglutide or tirzepatide peak was found.
Purity	**99.80 %** (mean of 3 vials; 99.57-99.95 %) by HPLC with UV detection at 214 nm.
Conformity between vials	**Consistent.** The same peptide is the main compound of every vial (retatrutide); Content of every vial within +/- 5 % of the three-vial mean; Purity of every vial within +/- 0.5 percentage points of the mean; Same impurity profile: no impurity of 0.3 % or more in one vial only: met. Criteria are the laboratory's batch-consistency limits for 3 vials; a formal content-uniformity test (USP <905>) needs 10 units.

Impurities

Every peak other than retatrutide found in the vials, as a share of the UV peak area at 214 nm:

Peak (min)	Vial D3	Vial E3	Vial F3	Mean	What it is
7.42	< 0.01 %	0.12 %	0.02 %	0.05 %	A small unidentified peak (too small for its mass to be measured).


Trace peaks below 0.10 % add up to 0.05 % (vial D3), 0.31 % (vial E3), 0.11 % (vial F3). '-' = not found in that vial.


Net content

Vial	Net content	% of label
Vial D3	59.2 mg	98.7 %
Vial E3	58.4 mg	97.4 %
Vial F3	55.2 mg	92.1 %
Average	57.6 mg	96.1 %
Difference	4.00 mg (RSD 3.7 %)	6.7 points

Content is the mean of every injection of the vial's solution. Difference = largest minus smallest vial.

Zoomed views





Chain of custody

Receipt photograph of the vials: 29 Oct 2026 12:10, orange cap (6A-RT 60 mg). Sample preparation was video-recorded on 29 Oct 2026 (2 recordings, each identified by its SHA-256 fingerprint): 60mg reta pt1.mp4 (103 s, 02f5816815eaab4fe3983b588e5af6c7ed034f81fcdf5e94ac4fe5ae6b7ed1b6); 60mg reta pt2.mp4 (103 s, 9d10ab73a062142adf5c527d117d14d8425fd8c8c59a9050fe073ec5e6f33936).

How it was tested

Liquid chromatography with UV and mass-spectrometry detection: Agilent 1290 Infinity II LC with a 6490 triple-quadrupole mass spectrometer. Column Polaris C18-A, 2.0 x 150 mm, 55 °C; water and acetonitrile, each with 0.1 % formic acid. Purity: UV peak area at 214 nm. Identity: molecular mass and retention time against a reference standard. Content: UV at 220 nm against a retatrutide reference standard; the whole vial was dissolved. Each vial was made up in 3 mL and then diluted 1 in 10, in 20 % acetonitrile / 80 % water with 0.1 % formic acid.

Notes

Results apply only to the vials as received and tested. Purity is a share of the UV peak area, not a weight percentage. Identity is by molecular mass and retention time; the amino-acid sequence was not checked.

APPROVED FOR RELEASE

Signed electronically by a Gold Standard Analytics lab technician at release.
The signature is at the bottom of page 1; the release record, the last page of this certificate, gives the date and verification code.

Gold Standard Analytics

goldstandardanalytics.com

Release record

Report GSA-COA-000078-RETA60-20261031-8 · Certificate GSA-2026-889557

Customer and order	6A Labs · GSA-2026-000078
Sample and report	078-RETA60 · Retatrutide 60 mg Certificate of Analysis
Report reference	GSA-COA-000078-RETA60-20261031-8
Certificate accession	GSA-2026-889557
Released and signed by	Ian Ebert, Laboratory Director
Date and time (UTC)	2026-11-05 04:46:16Z
Signature meaning	Approved for release. The signer reviewed this report and approved its release to its customer.
Approval reference	4686f198-3176-4032-ba57-ff19f4f59d33
Electronic signature	Signed electronically in a signed-in GSA staff account.
Original report SHA-256	16d2c5803091718cec8ef2c3aeb06c53e48fc00dee221b1bea33a8e86f88953f
Verify this certificate	https://goldstandardanalytics.com/coa/GSA-2026-889557

Scan to view this certificate online

Signature



Ian Ebert, Laboratory Director